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Emerging infectious disease
Microbial infections are as old as the hosts they sicken, but interest in the emergence of pathogens and the
diseases they cause has been accelerating rapidly. The term ‘emerging infectious disease’ was coined in the
mid-1900s to describe changes in disease dynamics in the modern era. Both the term and the phenomena it is
meant to characterize have evolved and diversified over time, leading to inconsistencies and confusion. Here,
we review the evolution of the term ‘emerging infectious disease’ (EID) in the literature as applied to human
hosts. We examine the pathways (e.g., speciation or strain differentiation in the causative agent vs. rapid geo-
graphic expansion of an existing pathogen) by which diseases emerge.We propose a new framework for disease
and pathogen emergence to improve prioritization. Andwe illustrate how the operational definition of an EID af-
fects conclusions concerning the pathways by which diseases emerge and the ecological and socioeconomic
drivers that elicit emergence. As EIDs appear to be increasing globally, and resources for science level off or de-
cline, the research community is pushed to prioritize its focus on themost threatening diseases, riskiest potential
pathogens, and the places they occur. The working definition of emerging infectious diseases and pathogens
plays a crucial role in prioritization, but we argue that the current definitions may be impeding these efforts.
We propose a new framework for classifying pathogens and diseases as “emerging” that distinguishes EIDs
from emerging pathogens and novel potential pathogens. We suggest prioritization of: 1) EIDs for adaptation
and mitigation, 2) emerging pathogens for preventive measures, and 3) novel potential pathogens for intensive
surveillance.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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‘Emerging infectious disease’ — evolution of a term
“I always like informally to define emerging infections as those thatwould
knock a really important story off the front page of the newspaper.”
[Stephen Morse [1]]
Infectious disease events in humans, such as the initial outbreaks of
measles in early agrarian societies 11,000 years ago, the geographic
scope of the Black Death in the 14th century, and the introduction of
smallpox to the New World in the 1500s undoubtedly would have
made the ‘front page’ news of the time. These events have shaped
human history for millennia, yet a growing body of literature suggests
that host–pathogen dynamics are changing and giving rise to a novel
cohort of ‘emerging infectious diseases’ (EIDs). Conceptualizations and
definitions of EIDs have evolved in recent decades, affecting how epide-
miologists and others interpret the causes and consequences of disease
emergence. Belowwe explore the changing definitions of EIDs and their
consequences, and offer an alternative framework that we hope
will stimulate new efforts to better prioritize proactive and reactive
approaches to disease emergence.
The earliest publications with ‘emerging disease’, ‘emerging patho-
gen’, or variations thereof in the title appeared in the 1950s and focused
primarily on single disease events in livestock. Among these is a 1962
report on the introduction of Equine Piroplasmosis into the United
States [2]. The paper's title, Equine Piroplasmosis — Another Emerging
Disease, suggests that emergence was already a recognized phenome-
non by the early 1960s. The 1970s and 1980s saw reports on EIDs in
humans, livestock, pets, and in association with food crops [3–8]. The
first review of the topic, published in 1971 [9], chronicled the important
EIDs of the time (cholera, diphtheria, gonorrhea, cryptococcosis, malar-
ia, and hemorrhagic fevers to name a few), but did not provide a specific
definition for emerging infectious diseases or emerging pathogens. Nev-
ertheless, the final sentences established what most EID researchers
would agreewith today— change is to be expected. “Themicrobiological
system is closely allied with man; changes in the environment alter his
relationship with organisms whether they be beneficial, symbiotic, or
pathogenic. Man's way of life, his human behavior, his technological
advances, his mere existence foster the conquest of some disease organisms,
the emergence of others, and his introduction to unfamiliar ones. The infec-
tious disease picture, therefore, is as subject to change as life itself [9].”
It was not until the late 1980s/early 1990s that organized scientific
groups like the Institute of Medicine (IOM) became publically con-
cerned with EIDs [10,11]. Institutional interest in EIDs manifested
through conferences, reports, and publications that sparked multi-
disciplinary focus on the topic and set the stage for the surge in research
that followed (Fig. 1) [10,12,13]. Two scientists in particular were espe-
cially influential in these years, Stephen Morse and Joshua Lederberg.
Morse'swork on viruses provided someof thefirst publisheddefinitions
of emergence. “Wemay use the term ‘emerging viruses’ to refer to viruses
that either have newly appeared in the population or are rapidly expanding
their range, with a corresponding increase in cases of disease [12,14].”
Morse's opinion was that despite appearances, emerging viruses are
often not newly evolved organisms, but instead are existing viruses in
the process of invading new host groups or regions, a process he called
‘viral traffic’[12,14].
Arguably, it was the 1992 IOM study, Emerging Infections: Microbial
Threats to Health in the United States, co-authored by Lederberg, Robert
Shope and Stanley Oaks [10], that launched the current phase of
research on patterns, causes and consequences of emerging infectious
diseases. The establishment of the Program for Monitoring of Emerging
Diseases (ProMED) and the Centers for Disease Control and Prevention's
(CDC) journal Emerging Infectious Diseases soon followed, as did initial
research aimed at identifying the general characteristics and drivers of
emerging diseases [15,16]. EIDs were defined in the IOM (1992) report
as “clinically distinct conditions whose incidence in humans has increased”
while re-emergencewas defined as “the reappearance of a knowndisease
Fig. 1. Emerging infectious disease publications and citations over time. We searched the Science Citation Index Expanded (ISI Web of Science) for papers published from 1900 to 2013
with English titles containing specific disease and pathogen emergence terms. Abstracts are not reliably available before 1990 so only titles were searched for 1900 to 1990. Our advanced
search stringwas as follows: TI= (“emerging infect*”) OR TI= (“emerging disease*”) ORTI= (“emerging pathogen*”) OR TI= (“emerging virus”) ORTI= (“emerging bacteria”) OR TI=
(“emerging helminth”) OR TI = (“emerging parasit*”) OR TI = (“emerging fung*”). Returned articles were used to create a graphic illustration of the number of published reports and
citations of these reports in each year. Events, reports and publications influential in the development of the field if emerging infectious diseases are noted.
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after a decline in its incidence” [10]. The CDC was the first to add a
timeframe to the definition, promulgating EIDs as “diseases of infectious
origin whose incidence in humans has increased within the past two de-
cades or threatens to increase in the near future [11]”.
The first attempts to identify which of themore than 1400 infectious
agents known to humans were causing, or were likely to cause, emerg-
ing diseases and to use these lists to identify EID risk factors occurred in
the 21st century. Seminal work conducted during this period began to
shed light on the myriad linkages between human, wildlife and live-
stock hosts that result in pathogen spillover (successful transmission
from one host species to another) and subsequent emergence events
[17]. Taylor et al. [18] produced the first list and quantitative study of
emerging pathogens (not diseases) which they defined as, “… those
that have appeared in a human population for the first time, or have
occurred previously but are increasing in incidence or expanding into
areas where they had not previously been reported, usually over the last
20 years.” They noted, “Some definitions of emerging also include recently
discovered aetiological agents of already-described diseases. However, if
there was no evidence that such a pathogen was increasing in incidence,
it was not regarded in this database as emerging.” Their tally identified
175 pathogenic species associated with emerging diseases, 75% of
which were zoonotic (transmitted to humans from non-human
vertebrates). Viruses and protozoa were deemed especially likely to
emerge while helminthes were not, and no effect of transmission type
(i.e., vector-borne vs. direct transmission) was detected. This [18]
research paved the way for additional studies on the risk factors for
human disease emergence. One of these studies updated the list assem-
bled by Taylor et al., examined the relationship between host range and
pathogen emergence, and identified social and environmental causal
factors, i.e., “drivers” [19]. This study also revealed that emerging zoo-
notic pathogens can be maintained in a wide variety of non-human
hosts, tend to have broad host ranges, and are largely the result of
human impacts on the landscape (e.g., deforestation to support agricul-
ture and livestock) and changinghumandemographics (e.g., population
density in particular) [19].
The definition of emerging infectious disease continued to evolve
with the 2003 update of the 1992 IOM report: “… either a newly recog-
nized, clinically distinct infectious disease, or a known infectious disease
whose reported incidence is increasing in a given place or among a specific
population” [20]. Five years later Jones et al. [21] published what is
among the most cited EID papers to date. The authors presented the
first spatiotemporal analysis of EID events (the original case or cluster
of cases representing an infectious disease emerging in human popula-
tions for the first time) and their causal factors. They defined an emerg-
ing infectious disease as that which has “recently increased in incidence,
impact or geographic range. Specifically, it is caused by a pathogen that
has recently evolved or entered the human population for the first time,
or which has occurred previously, but is increasing in incidence or
expanding into an area in which it has not previously been reported, or
which has significantly changed its pathological or clinical presentation.”
Their compilation and analyses of 335 EID events was novel in a few
ways. First, the report provided quantitative evidence for the long-
held assumption that EIDs were increasing over time in the human
population (since 1940). Second, each individual drug-resistant
microbial strain was counted as a unique pathogen in the dataset, lead-
ing to the new finding that bacteria were more likely to be emerging
pathogens than viruses. Third, using a method that accounted for an
expected geographically-based bias in the reporting of EIDs, potential
future EID hotspotswere predicted in low andmiddle income countries
where high human population density and biological diversity overlap;
the very regions of theworld where disease surveillance ismost lacking
[21].
Advances in infectious disease research have been rapid and
multi-disciplinary in the last twenty years, and have been influential
in resource allocation to improve EID prediction and prevention (e.g.,
USAID's Emerging Pandemic Threats Program [22]). What are the next
steps for the field? How can the infectious disease research community
better understand the macro-ecology of emerging infectious diseases?
How can we sharpen our focus to be better at preventing and
responding to the next influenza strain, coronavirus or Ebola outbreak?
The working definition of emerging infectious diseases and pathogens
plays a crucial role in efforts to do so. An evolving and vague or inconsis-
tent definition is likely impeding these efforts [23].
In the sections below,we: 1) examine the pathways (how) bywhich
diseases emerge; 2) propose a new framework for emergence to inform
prioritization efforts; and 3) illustrate how the operational definition of
an EID affects conclusions concerning the ecological and socioeconomic
drivers (e.g., land use change, antimicrobial agent use) that elicit
emergence.
Pathways to emergence
The attributes that constitute emergence among pathogens and dis-
eases have varied over time and space, as well as between studies. The
medical and public health fields tend to focus on emerging diseases
[10,20], while ecologists are largely interested in their causal agents —
emerging pathogens [18,19,21]. By chronicling changes in the definition
of EIDs in the literature, we identified seven ‘pathways’ that researchers
have used to identify diseases and pathogens as emerging in humans:
1) when a disease increases in incidence, 2) when a disease increases
in impact (as measured, for example, by the associated disability in
terms of morbidity and mortality), 3) when a disease increases in geo-
graphic range, 4) when a pathogen has undergone recent evolutionary
change, 5) when a pathogen is detected the human population for the
first time, 6) when a pathogen significantly changes its pathology or
clinical presentation, or 7) when a pathogen is discovered for the first
time. Collectively, these pathways capture nearly all the ways in
which pathogens and the diseases they cause can change in the
human population. These seven pathways have been used predomi-
nantly to identify emergence, but have been overlooked in macro-
scale analyses of EIDs [18,19,21]. Neglect of the pathways used to desig-
nate diseases as emerging has left some important questions unan-
swered. Do most EIDs emerge via one or multiple pathways? Are
some pathways more common than others in the emergence process?
We consider these questions using a subset of chronicled EID events.
We took a disproportionate random sample from the database of
335 pathogens reported by Jones et al. [21] as causing EID events since
1940. Using Stata 10.0, we selected a sample with equal numbers of vi-
ruses, both zoonotic (n= 20) and non-zoonotic (n= 20), and bacteria,
both zoonotic (n=20) andnon-zoonotic (n=20), yielding a total of 80
events. A disproportionate sample was selected in this manner to
increase the power to detect associations between pathogen type or
host type and pathways or drivers. We focused on bacteria and viruses
as these taxonomic groups are best studied (e.g., as compared to emerg-
ing helminths) and represent the majority of EID events.
Literature surveys were conducted to identify the pathways associ-
ated with each of the 80 EID events. The original references cited in
Jones et al. were reviewed first, followed by PubMed andGoogle Scholar
searches for the specific event until sufficient informationwas compiled
to categorize events by one, some, or all of the seven proposed pathways
of emergence. After examining references from Jones et al., if the disease
pathogen could not be categorized sufficiently, we then searched
PubMed by the name of the pathogen, followed by the year of the
event, noted in Jones et al. If the pathogen still could not be sufficiently
categorized based on results from the PubMed search, the same
searches were conducted using Google Scholar. For a more detailed ex-
planation of EID events, associated references, and assigned pathways
see the supplemental information.
Our findings suggest that emergence rarely occurs as a result of only
one pathway (Table 1). In fact, all of the 80 events we examined
emerged via two to three pathways (38 events by two pathways, 33
events by three pathways, 9 events by four pathways). More than 40%
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of events were characterized by the pathways ‘detected in the human
population for the first time’ and ‘newly discovered’. The only pathway
not associated with any EID event in our sample was ‘changing in pa-
thology or clinical presentation’. The broad way in which EIDs have
been identified previously (by demonstrating one or more pathways
of emergence) has the potential to mask critically important heteroge-
neity in these events, their drivers, and future hotspots of EID events.
A new framework for classifying emergence
To open a dialog on how the definition of EID affects the interpreta-
tion of drivers and biogeography of emergence, we here propose a new
definitional framework. Our framework distinguishes between four
stages of emerging diseases and pathogens and ranks them in decreas-
ing order of immediate public health impact for prioritization purposes:
1) emerging infectious diseases, 2) emerging pathogens, 3) novel
potential pathogens, and 4) submerging infectious diseases and
pathogens. We present the framework in a decision tree (Fig. 2) and
apply it to the subset of EID events described in the preceding section.
Emerging infectious diseases (EIDs)
Emerging infectious diseases (EIDs) are those that have a clear det-
rimental impact on a human host population. Impact can occur both
over space and time and is an inherent outcome of the spread of infec-
tious disease to new human hosts. The pathways that constitute an
emerging infectious disease are the three described in the most recent
literature: 1)when a disease increases in incidence, 2)when a disease in-
creases in impact, and 3) when a disease increases in geographic range.
The question raised above, what constitutes impact, is key here. The im-
pact of any given infectious disease can vary greatly between host indi-
viduals, populations, and places. Highly virulent pathogens, those that
are challenging to treat, and thosewith high basic reproductive numbers
(R0: the average number of cases one infected individual causes in a
completely susceptible population) can result in widespread morbidity
and mortality that in the worst cases also cause public unrest and eco-
nomic loss. SARS and Ebola serve as examples of EIDs. Moving quickly
via the commercial aviation network, SARS spread to 29 countries and
infectedmore than 8000people in eightmonths, costing the global econ-
omy 30–100 billion USD [24]. SARS in 2002–2003 was ‘emerging’ due to
its increase in geographic range, impact and incidence. Similarly, the
emergence of Ebola virus in several parts of Africa is another clear case
of an EID. The original outbreaks in the Democratic Republic of Congo
(then Zaire) and South Sudan (then Sudan) in 1976 involved N600
caseswith N70% case fatality. Periodic outbreaks in Central Africa contin-
ued throughout the late 20th and early 21st Centuries, affecting dozens
to hundreds of people each time, with similarly high fatality rates [25].
The first cases of the current Ebola virus outbreak were confirmed in
March 2014, and as of the end of October 2014 there were N6500 cases
in Liberia, N5300 in Sierra Leone, and N1600 in Guinea, with other
laboratory-confirmed cases in Mali, Senegal, Nigeria, Spain, and the
United States [26,27]. Ebola clearly meets the definition of an EID given
the increase in the disease's incidence, impact (in terms of morbidity
and mortality) and geographic range.
Emerging pathogens (EPs)
Emerging pathogens (EPs) are those characterized by the following
pathways: 4) when a pathogen has undergone recent, rapid evolution-
ary change tantamount to speciation or strain differentiation, 5) when a
pathogen is detected the human population for the first time, 6)when a
pathogen significantly changes its pathology or clinical presentation, or
7)when a pathogen is discovered for the first time. Emerging pathogens
are distinguished from the next stage, novel potential pathogens, in that
there is clear evidence that they can cause disease in humans. Relative
to emerging infectious diseases, however, emerging pathogens (in
their present state) do not cause significant levels of morbidity or mor-
tality. This is not to imply that they do not have the potential to become
an emerging infectious disease; somewill and somemaynever. Inmany
cases emerging pathogens will have been identified as infectious in a
single or small number of local cases. Examples of emerging pathogens
include many multi-drug resistant microbes. For these pathogens, the
potential health impact will vary with the availability and accessibility
of treatment options. Another example of an emerging pathogen is
Jamestown Canyon virus. Jamestown Canyon virus is a member of the
California serogroup of bunyaviruses spread by mosquitoes from the
typical cervid reservoir. Though this pathogenwas originally discovered
in the 1960s in mosquitoes, only 15 human cases have been reported in
Table 1
Disease emergence pathways.
Pathways of emergence EID events
N (%)
1. Increasing in incidence 80 (100)
2. Increasing impact 31 (39)
3. Increasing in geographic range 7 (9)
4. Newly evolved 23 (29)
5. Detected in the human population for the first time 34 (43)
6. Changing pathology or clinical presentation 0 (0)
7. Newly discovered 36 (45)
Fig. 2.A decision tree applying a new framework for emergence.We redefined EID events as: 1. EIDs: those that increase in impact or increase in geographic range. 2. Emerging pathogens
(EPs): those that have undergone recent evolutionary change, are entering detected in the human population for the first time, a pathogen has significantly changed its pathology or clin-
ical presentation, or are newly discovered and show evidence that their presence in a human host causes clinical illness. 3. Novel potential pathogens (NPPs): those that are characterized
by recent evolutionary change, are entering detected in the human population for the first time, or are newly discovered, but and show no evidence that their presence in a human host
causes clinical illness. 4. Submerging infectious disease or pathogen: those that are receding in impact due to human intervention or through natural means.
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the United States since 2004 [28]. The Jamestown Canyon virus is rare,
yet endemic in parts of the United States and Canada. Though it was
newly discovered in the 1960s and now found to cause illness in
humans, it is not increasing in incidence, impact, or geographic range.
Therefore, Jamestown Canyon virus is an emerging pathogen that
should be targeted for surveillance and prevention measures, but not
for the wide-scale mitigation efforts an EID would require.
Novel potential pathogens (NPPs)
Novel potential pathogens (NPPs) are also characterized by path-
ways 4, 5 and 7, but are distinct from emerging pathogens in that
there is no evidence that their presence in a human host causes clinical
illness. Novel potential pathogensmight include opportunisticmicrobes
that are typical members of a human host microbiome. Only under un-
usual circumstances might they become pathogenic; for example when
the human host becomes immune-compromised, the microbiome is al-
tered in a manner that allows a particular microbe to reach high abun-
dances and become pathogenic [29], or virulence increases due to a
genetic or physiological change. Other examples of novel potential
pathogens are those newly discovered in humans, but which do not
yet cause clinical illness. Simian foamy viruses (SFVs), retroviruses
highly prevalent in several animal species, are one example. Studies in
central Africa have demonstrated spillover of these viruses from
primates to primate hunters though to date there is no evidence that
infection causes clinical illness in the latter [30].
Submerging infectious diseases and pathogens
Submerging infectious diseases and pathogens are those receding in
scope and impact due to human intervention or through naturalmeans.
We have the power to reduce the impact, incidence and geographic
scope of emerging infectious diseases over time and so submergence
should be part of a prioritization framework. In a few extraordinary
cases, infectious diseases of global concern have been eliminated from
the planet. Smallpox was eradicated from the human population,
Rinderpest was eradicated from ungulates, and the end of Guinea
Worm looks to be within reach [31–33]. Not so long ago, Smallpox
and Rinderpest were harmful emerging infectious diseases. Smallpox
emerged in the New World during the Age of Exploration and went
on to decimate Native American populations, whereas Rinderpest was
introduced to Africa in the late 1800s andwiped out such large numbers
of domestic and wild ungulates that the entire southern part of the
continent experienced sweeping ecosystem change [34]. Both diseases
submerged over time, became endemic, and thanks to tireless human
effort are now a part of history. Submerging infectious diseases are
overlooked by the current EID literature, but an important stage in this
new framework is the power of science-based policy to reduce the
impact, incidence and geographic scope of emerging infectious diseases.
Applying the framework
We redefined the 80 EID events according to our new framework to
illustrate how the definition of EIDs affects biological conclusions
regarding both pathways and drivers of EIDs. When describing drivers
we considered all drivers assigned to at least five EID events (in our
subset of 80 EID events). This led to a categorical variable for drivers
that included: industry changes, international travel & commerce, land
use changes, antimicrobial agent use, human susceptibility to infec-
tion, and other. ‘Other’ was created by combining all other drivers
that were assigned to fewer than five EID events (e.g., breakdown in
public health measures, bushmeat consumption, climate & weather,
human demographics & behavior, war & famine, and unspecified).
After the reclassification of these EID events, only 41% of EID events
consideredmaintained the classification of an EID under our framework.
Over half (54%)were reclassified as EPs and 5% as NPPs (Table S1). Using
Pearson's chi-square test, EIDs and EPs were shown to have significantly
different drivers (p= 0.03; there were too few NPPs to consider; Fig. 3).
Whereas EIDs were largely associated with industrial change, interna-
tional trade and commerce, and ‘other drivers’, antimicrobial agent use
was the dominant driver of EPs. This new classification demonstrates
that the broad way in which EIDs have been categorized to date masks
critically important heterogeneity in these events, their drivers, and
therefore predictions of future occurrence (Fig. 3). These observations
underscore the need for a consistent, transparent definition of EID and
related concepts.
Stage shifts in the emergence process
Our ability to identify a stage shift (e.g., when anNPP becomes an EP,
when an EP becomes an EID, etc.) in the EID framework depends on
three overarching conditions. First, detecting a shift depends on who
is looking, when, and the factors that facilitate disease reporting, includ-
ing scientific infrastructure, openmedia and internet usage [35,36]. The
shift of SARS from an emerging pathogen to an emerging disease took
place over a matter of weeks. If Chinese public health officials had iden-
tified, contained and publically reported cases earlier, SARS might not
have had the global impact that it did [37]. Recognizing that there will
always be criticism during an epidemic, officials covering MERS-CoV
seem to have benefitted from the lessons of SARS. Newly discovered
cases are being reported in almost real-time to the public, and agencies
(including the Saudi Arabian Ministry of Health, European Centre for
Disease Prevention and Control, U.S. CDC and the WHO) are coordinat-
ing surveillance internationally.
Second, identifying a shift from emerging pathogen to emerging
disease depends on how we choose to quantify significant increases
and decreases in incidence, geographic range and impact. The research
community is just now considering empirical methods to accomplish
this. A recent proposal for segmented linear regression to examine
changes in the incidence of a specific disease in a defined location is a
promising start [38]. The next steps for suchmethodswill bemore effec-
tively controlling for the influence of surveillance effort, discovery bias
and reporting on incidence trends, adding a spatial dimension, and con-
sidering how best to calculate and track changes in impact. Related to
this last point, the research community needs to decide which stages of
emergence are most permeable to prevention and control efforts. This
is the third condition that influences our ability to identify stage shifts.
Our literature review reinforces the notion that the distribution and
impact of pathogens vary continuously in space and time, but when
these facts shouldmatter to public health is not straightforward. The eco-
nomic costs and R0 values of EIDs are twometrics that have been used to
quantify impact [39–42]. R0 is typically calculated retrospectively, after
diseases have emerged and are widely spread within a population and
can vary geographically or between host populations. New methods
from physics, based on the principles of network theory, offer the possi-
bility of real-time estimates of R0 [43] and potential for assessing and
comparing the impacts of emerging pathogens before they move to the
next stage. While Disability Adjusted Life Years (DALYs) have been
valuable in characterizing the global burden of many endemic and
chronic infectious diseases, their application to EIDs remains notably ab-
sent but potentially promising in estimating impacts.
Conclusion
We have reviewed the literature to describe the evolution of the
term emerging infectious disease, identified the major pathways of
emergence, presented a new framework for classifying pathogens and
diseases at varying levels of emergence, and laid out the challenges as-
sociated with the current definition of EIDs. We have shown that the
definition of an EID strongly affects our understanding of how and
why diseases emerge, which in turn informs efforts to prevent and
mitigate emergence. Ultimately, what the scientific and health
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communities want to understand is what causes pathogens and infec-
tious diseases to become increasing threats so that they can either
be prevented or mitigated quickly and efficiently. Having a consistent,
operational, and transparent definition of emergence and related con-
cepts is critical for this purpose, yet the current definition has drifted,
becoming less operational and less consistent. The framework we pro-
pose suggests a prioritization scheme that focuses on pathogens with
realized or likely imminent public health impact, but the impact thresh-
old remains elusive. We suggest that EIDs should be prioritized for ad-
aptation and mitigation, emerging pathogens for preventive measures,
and novel potential pathogens for intensive surveillance. We think
this new approach to emergence is likely to improve our ability to gen-
erate accurate generalizations about the patterns and processes
governing trends in infectious disease, which will be critical for future
efforts to protect global public health.
Acknowledgments
We thank Felicia Keesing for comments and suggestions that helped
to improve this manuscript. This work was made possible by grant
number 1R01GM100471-01 from the National Institute of General
Medical Sciences (NIGMS) at the National Institutes of Health and
support from the Brown University's Environmental Change Initiative
(GR30014).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.onehlt.2015.08.001.
References
[1] Microbial Evolution and Co-adaptation: A Tribute to the Life and Scientific Legacies
of Joshua Lederberg, Institute of Medicine, Washington, DC, 2009.
[2] F.D. Maurer, Equine piroplasmosis—another emerging disease, J. Am. Vet. Med.
Assoc. 141 (1962) 699–702.
[3] I. McCandlish, et al., Parvovirus infection, an emerging disease — sudden-death in
puppies and a new diarrhea syndrome in dogs, Vet. Rec. 105 (1979) 180.
[4] M. Blaser, Campylobacter— an emerging pathogen in food, J. Food Prot. 47 (1984) 824.
[5] P.A. Backman, D.B. Weaver, G. Morganjones, Soybean stem canker—an emerging
disease problem, Plant Dis. 69 (1985) 641–647.
[6] G.C. Dumoulin, et al., Mycobacterium avium complex, an emerging pathogen in
Massachusetts, J. Clin. Microbiol. 22 (1985) 9–12.
[7] M.P. Doyle, Update on emerging pathogens in foods, J. Food Prot. 50 (1987) 891.
[8] R.K. Tanwar, Polioencephalomalaci, an emerging disease of goats, Indian J. Anim. Sci.
57 (1987) 1–4.
[9] D.J. Sencer, Emerging diseases of man and animals, Annu. Rev. Microbiol. 25 (1971)
465–486.
[10] Emerging Infections: Microbial Threats to Health in the United States, Institute of
Medicine, Washington, DC, 1992.
[11] Addressing Emerging Infectious Diseases Threats: A Prevention Strategy for the United
StatesMMWR 43-RR-5 Centers for Disease Control and Prevention, Atlanta, 1994.
[12] S.S. Morse, A. Schluederberg, Emerging virus: the evolution of viruses and viral
diseases, J. Infect. Dis. 162 (1990) 1–7.
[13] S.S. Morse, Emerging viruses: defining the rules for viral traffic, Perspect. Biol. Med.
34 (1991) 387–409.
[14] S.S. Morse, S.S. Morse, Emerging Viruses, Oxford Univ. Press, NewYork 1996, pp. 10–28.
[15] C.J.L. Murray, A.D. Lopez (Eds.), The Global Burden of Disease, Harvard School of
Public Health, Cambridge, 1996 (1022 pp.).
[16] The World Health Report 1998—Life in the 21st Century: A Vision for All, World
Health Organization, Geneva, Switzerland, 1998.
[17] P. Daszak, A.A. Cunningham, A.D. Hyatt, Emerging infectious diseases of
wildlife—threats to biodiversity and human health, Science 287 (2000) 443–449.
[18] L.H. Taylor, S.M. Latham, M.E.J. Woolhouse, Risk factors for human disease emer-
gence, Philos. Trans. R. Soc. Lond. 356 (2001) 983–989.
[19] M.E.J. Woolhouse, S. Gowtage-Sequeria, Host range and emerging and reemerging
pathogens, EID 11 (2005) 1842–1847.
Fig. 3.Difference in driver distribution amongEIDs and EPs. Literature surveys of the 80 randomly selected EID events from Jones et al. [21] uncovered enoughdetail for us to apply the new
framework (see supplementary information). This new classification revealed a significant difference in the distribution of causal drivers associated with EIDs versus EPs (p = 0.03).
22 S.R. Rosenthal et al. / One Health 1 (2015) 17–23
[20] Microbial Threats to Health: Emergence, Detection, and Response, Institute of
Medicine, Washington, DC, 2003.
[21] K.E. Jones, et al., Global trends in emerging infectious diseases, Nature 451 (2008)
990–993.
[22] U. S. Agency for International Development, Emerging Pandemic Threats Program,
http://www.usaid.gov/news-information/fact-sheets/emerging-pandemic-threats-
program, 2012.
[23] P. Farmer, Social inequalities and emerging infectious diseases, Emerg. Infect. Dis. 2
(1996) 259–269.
[24] M.R. Keogh-Brown, R.D. Smith, The economic impact of SARS: how does the reality
match the predictions? Health Policy 88 (2008) 110–120.
[25] Centers for Disease Control and Prevention, Ebola (Ebola Virus Disease). Outbreaks
Chronology: Ebola Virus Disease, http://www.cdc.gov/vhf/ebola/outbreaks/history/
chronology.html, 2015.
[26] Centers for Disease Control and Prevention, 2014 Ebola Outbreak in West Africa,
http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html, 2014.
[27] World Health Organization, Ebola Virus Disease, http://www.who.int/mediacentre/
factsheets/fs103/en/, 2014.
[28] Human Jamestown Canyon Virus Infection—Montana, 2009, MMWR 60 (20) (2011)
652–655 (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6020a3.htm).
[29] I. Cho, M.J. Blaser, The human microbiome: at the interface of health and disease,
Nat. Rev. Genet. 13 (2012) 260–270.
[30] S. Calattini, et al., Simian foamy virus transmission from apes to humans, rural
Cameroon, Emerg. Infect. Dis. 13 (2007) 1314–1320.
[31] J.G. Breman, I. Arita, The confirmation and maintenance of smallpox eradication, N.
Engl. J. Med. 303 (1980) 1263–1273.
[32] M. Barry, The tail end of Guinea worm—global eradication without a drug or a vac-
cine, N. Engl. J. Med. 356 (2007) 2561–2564.
[33] D.M. Morens, E.C. Holmes, A.S. Davis, J.K. Taubenberger, Global Rinderpest eradica-
tion: lessons learned and why humans should celebrate too, J. Infect. Dis. 204
(2011) 502–505.
[34] W.H. McNeill, Plagues and Peoples, Basil Blackwell, Oxford, 1977 (368 pp.).
[35] L.C. Madoff, J.P. Woodall, The internet and the global monitoring of emerging dis-
eases: lessons from the first 10 years of ProMED-mail, Arch. Med. Res. 36 (2005)
724–730.
[36] K. Wilson, J.S. Brownstein, Early detection of disease outbreaks using the Internet,
Can. Med. Assoc. J. 180 (2009) 829–831.
[37] R.F. Breiman, et al., Role of China in the quest to define and control severe acute re-
spiratory syndrome, Emerg. Infect. Dis. 9 (2003) 1037–1041.
[38] S. Funk, T.L. Bogich, K.E. Jones, A.M. Kilpatrick, P. Daszak, Quantifying trends in dis-
ease impact to produce a reproducible definition of an emerging infectious disease,
PLoS One 8 (2013).
[39] S.P. Luby, et al., Recurrent zoonotic transmission of Nipah virus into humans,
Bangladesh, 2001–2007, Emerg. Infect. Dis. 15 (2009) 1229–1235.
[40] M.P. Ward, D. Maftei, C. Apostu, A. Suru, Estimation of the basic reproductive num-
ber (R0) for epidemic, highly pathogenic avian influenza subtype H5N1 spread,
Epidemiol. Infect. 137 (2009) 219–226.
[41] M. Eichner, K. Dietz, Transmission potential of smallpox: estimates based on de-
tailed data from an outbreak, Am. J. Epidemiol. 158 (2003) 110–117.
[42] The Economic and Social Impact of Emerging Infectious Disease: Mitiga-
tion Through Detection, Research, and Response, Marsh Inc., 2008 (http://www.
healthcare.philips.com/main/shared/assets/documents/bioshield/ecoandsocialim-
pactofemerginginfectiousdisease_111208.pdf).
[43] B. Davoudi, et al., Early real-time estimation of the basic reproduction number of
emerging infectious diseases, Phys. Rev. X 2 (2012) 031005.
23S.R. Rosenthal et al. / One Health 1 (2015) 17–23
